U.S. Markets open in 1 hr 23 mins
  • S&P Futures

    3,852.50
    +7.50 (+0.20%)
     
  • Dow Futures

    31,149.00
    +53.00 (+0.17%)
     
  • Nasdaq Futures

    13,347.25
    +53.00 (+0.40%)
     
  • Russell 2000 Futures

    2,163.10
    +5.40 (+0.25%)
     
  • Crude Oil

    53.02
    -0.29 (-0.54%)
     
  • Gold

    1,866.80
    +0.30 (+0.02%)
     
  • Silver

    25.90
    +0.13 (+0.50%)
     
  • EUR/USD

    1.2155
    +0.0040 (+0.3282%)
     
  • 10-Yr Bond

    1.0900
    0.0000 (0.00%)
     
  • Vix

    21.30
    -1.94 (-8.35%)
     
  • GBP/USD

    1.3717
    +0.0062 (+0.4540%)
     
  • USD/JPY

    103.4040
    -0.1660 (-0.1603%)
     
  • BTC-USD

    32,381.48
    -1,120.62 (-3.34%)
     
  • CMC Crypto 200

    642.99
    -36.92 (-5.43%)
     
  • FTSE 100

    6,747.33
    +6.94 (+0.10%)
     
  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference

Editas Medicine, Inc.
·1 min read

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021, at 10:50 a.m. ET.

A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Investors
Editas Medicine Investor Relations
(617) 401-9052
ir@editasmed.com

Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com